OKYO Pharma Limited
$1.64 +$0.09 (+5.81%) 1D Market openKey Metrics
The Story So Far
LAST 6 MONTHS PRIMARY SOURCES ONLY-
Jul 20
From its Feb 12 high, the share price fell 37%.
Peak close $2.17 on Feb 12; trough close $1.37 on Jul 20. The drawdown is the fact — the chapters around it are the context.
RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -37% -
Jul 16
Money rotated out of high-beta cohorts market-wide.
High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.
RECEIPT: ROTATION GAUGE, LIVE -
Feb 13
The stock moved -19.4% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Feb 13 -
Feb 12
The stock moved +11.3% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Feb 12
The story updates itself as events post · The wolf reports; you decide
Snapshot
About OKYO Pharma Limited
OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort.
Wolf Grade COMING SOON
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.